RxDoctor Payments Data

Chrystal Pratt

Psychiatric/Mental Health · Latrobe, PANPI 1437919925

Payments from drug & device makers

$3,252in general payments, 2019–2025

Across 226 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Vanda Pharmaceuticals Inc.$370
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$332
  • Otsuka America Pharmaceutical, Inc.$270
  • Neurocrine Biosciences, Inc.$231
  • Teva Pharmaceuticals USA, Inc.$228
  • plus $593 from 8 others

What the payments were for

  • Food & beverage$3,252100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,252 in reported general payments places this provider in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,868
Medicare patients
17
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl48$47,542
Lisdexamfetamine Dimesylate16$3,876
Aripiprazole61$2,011
Atomoxetine Hcl20$1,517
Hydroxyzine Hcl113$1,231
Vilazodone Hcl12$1,133
Buspirone Hcl101$1,084
Sertraline Hcl69$771
Mirtazapine66$767
Venlafaxine Hcl ErVenlafaxine Hcl82$686
Hydroxyzine Pamoate62$538
Olanzapine32$520
Bupropion Hcl SrBupropion Hcl35$489
Clonazepam49$455
Gabapentin41$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,229$47,54248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Latrobe

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →